DUBLIN and SAN DIEGO - March 14, 2015 - Medtronic plc (MDT) today announced initial clinical outcomes for its next-generation CoreValve ® Evolut (TM) R System. At 30-days, the new recapturable, ...

Medtronic plcMDT recently announced the commencement of a new real-world study – the Evolut R Forward Clinical trial – subsequent to reporting patients’ enrollment in this multi-center, single-arm ...

Medtronic has gained reimbursement approval for its CoreValve Evolut R transcatheter aortic valve in Japan and is now launching the device, making it the first recapturable TAVR system in the country.

The University of Michigan Frankel Cardiovascular Center is one of the first hospitals in the country to implant Medtronic's new investigational device during transcatheter aortic valve replacement ...

CE Mark Approval Received for New 26 mm and 29 mm Valves MINNEAPOLIS - Medtronic plc today announced CE (Conformité Européene) Mark for the 26 mm and 29 mm sizes of the CoreValve® Evolut(TM) R System, ...

NEW ORLEANS -- Accruing clinical data continue to suggest that the choice between transcatheter aortic valve replacement (TAVR) and surgery is not an easy one for patients at low surgical risk who are ...

Next-Generation TAVI System Offers Ability to Recapture and Reposition During Deployment MINNEAPOLIS - Medtronic, Inc. today announced CE (Conformité Européene) Mark for the 23 mm CoreValve® Evolut(TM ...

The Medtronic CoreValve Evolut R transcatheter aortic valve replacement system has received FDA approval. Medtronic and Edwards Lifesciences continue the transcatheter aortic valve replacement (TAVR) ...

Results from FORWARD and STS/ACC TVT Registry Demonstrate High Survival and Low Rate of All Stroke for Next-Generation TAVR Device in Everyday Clinical Practice DUBLIN and WASHINGTON, DC - Oct. 31, ...

DUBLIN, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system ...

Medtronicplc 's MDT next-generation transcatheter aortic valve replacement (TAVR) device - the CoreValve Evolut R System - is now commercially available in the U.S. market following its approval by ...